A first-in-human (FIH), phase I, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of AK119, a humanized monoclonal antibody targeting the CD73, was conducted with the future aim of treating COVID-19 patients (NCT04516564) (153). This evidence concerns the gene NT5E and COVID-19.